INTRODUCTION
Skin and soft tissue infections (SSTIs) represent a common reason for admission to the emergency department and a frequent cause of morbidity both in the community and in the hospital settings [1] . The clinical spectrum of SSTIs ranges from mild forms of skin infections to life-threatening diseases. For this reason, several classifications of SSTI have been proposed using variable definitions of disease severity and extension [2] . As a consequence of SSTI heterogeneity, a lack of clear definition of disease improvement following antimicrobial therapy has been reported. For this reason, in 2010 the United States Food and Drug Administration (FDA) defined a group of diseases -including cellulitis, erysipelas, major skin abscesses, and wound infections with a minimum lesion surface area of 75 cm 2 -as acute bacterial skin and skin-structure infection (ABSSSI; FDA) [3] .
Although new definitions of SSTI have become available, the cause of these infections has remained substantially stable. Staphylococcus aureus still represents the most common cause of SSTI, and methicillin-resistant S. aureus (MRSA) is often the most frequently isolated pathogen in complicated forms of skin and soft-tissue infections (cSSTIs) [4] .
Hospital admission to treat cSSTIs with intravenous antibiotics along with an increase of drug-resistant bacteria such as MRSA impact on duration of hospitalization, healthcare costs, and patient's morbidity. New therapeutic options currently offer MRSA coverage as well as the possibility for intravenous to oral switch or weekly administration. Although data from real-world studies on new antimicrobials become available, clinicians need clear direction on how to optimize the treatment of SSTIs in order to avoid prolonged hospitalizations and extra costs. Here we review the evidence for early intravenous to oral switch and early hospital discharge for patients with SSTIs. New therapeutic options that have been studied for the treatment of SSTIs and represent promising option to facilitate the optimal management of these infections are also reviewed.
TREATMENT OPTIMIZATION FOR SKIN AND SOFT-TISSUE INFECTIONS
The management of SSTIs depends on their clinical presentation and on the severity of the infection. There are significant challenges in the treatment of SSTI, including the management of recurrences, the overuse of broad spectrum and intravenous antibiotics, and the difficulty in establishing the optimal timing to initiate rescue therapy, to switch to oral therapy including compliance issues or to discontinue antimicrobial treatment [5, 6] .
The decision to initiate intravenous therapy and to determine hospital care should be based on individual clinical circumstances such as disease severity and patient comorbidities, especially for immunocompromised patients [7, 8] .
On the basis of the 2010 FDA recommendations, a new primary endpoint for development of antimicrobials to treat SSTIs was set assessing 48-72 h improvement instead of the traditional test-of-cure with resolution of signs and symptoms of infection 7-14 days after the end of treatment [9] . Recent clinical trials have demonstrated concordance between early clinical response at 48 h and the posttherapy evaluation.
In clinical practice, patients with SSTIs show improvement within 48 h of antimicrobial therapy, although visible improvement of clinical manifestations may take 72 h [10] .
Few studies have analyzed the factors associated with clinical failure in patients with SSTIs. Female sex, cardiovascular disease, high BMI, presence of cellulitis, inadequate empiric therapy, disease severity, and inadequate or delayed surgical source control such as lack of abscess drainage have been associated with reduced clinical response [11, 12] . Among obese patients, careful evaluation of antibiotic dosing is important to avoid drug underexposure and treatment failure [13] .
Despite a relatively low risk of complications, readmissions, or mortality associated with SSTI, patients often remain hospitalized for the entire duration of treatment. Evaluation within the first 72 h can direct clinicians to de-escalate treatment to a narrower spectrum agent, to switch from intravenous to oral therapy or consider outpatient parenteral antibiotic therapy (OPAT), to evaluate the need for surgery, or to discharge the patient. Several strategies for the management of SSTIs aim to reduce the hospital length of stay (LOS). Factors associated to increased LOS among patients with cSSTIs include length of intravenous therapy, history of drug abuse, and high comorbidity [14, 15] . In addition, deep or extensive cellulitis (versus surgical site or posttraumatic wound infection), infection in the torso or abdomen, late infections (!4 days after admission), and severe sepsis have also been associated with longer LOS [14, 15] . Delayed antibiotic treatment (!3 days after SSTI diagnosis), inappropriate empirical therapy, absence of oral antibiotic switch options or OPAT availability may contribute to increase LOS along with physicians' lack of awareness of treatment administration options or specific protocols for SSTI management [14, 15] .
Early switch to oral therapy is recommended if all inclusion criteria are fulfilled and if an appropriate oral regimen is available (Table 1) . Exclusion criteria for early switch include cutaneous abscess that have not been treated with incision and drainage, severe soft-tissue infection, or local complication (osteomyelitis or septic arthritis). Early discharge could be performed in patients with early
KEY POINTS
Hospitalization is often required to treat complicated skin and soft tissue infections (cSSTIs) with intravenous antibiotics, especially for infections caused by drugresistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA).
Early (<72 h from diagnosis) assessment of clinical response to treatment can help clinician decisions to switch to oral treatment and discharge the patient.
Early switch to oral treatment and early patient discharge should always be considered in the management of cSSTIs in order to reduce hospitalassociated costs and risks.
New therapeutic options currently offer MRSA coverage as well as the possibility for intravenous to oral switch or weekly administration, allowing for patients' early discharge and reducing costs.
switch eligibility criteria and no other limitations (Table 1) . Alternatively, patients could be discharged with suitable OPAT, although this option may require additional resources that are not always available [16] .
THE ROLE OF NEW ANTIMICROBIALS FOR EARLY SWITCH AND EARLY DISCHARGE IN COMPLICATED SKIN AND SOFT TISSUE INFECTIONS
In a large retrospective, multicenter study Nathwani et al. tried to describe real-world treatment patterns and potential opportunities for early switch from intravenous to oral treatment and early discharge in hospitalized patients with cSSTIs because of MRSA in Europe during the period 2010-2011. Overall, 33.6% of patients met early switch criteria and could have discontinued intravenous treatment 6.0 AE 5.5 days earlier, and 37.9% met early discharge criteria and could have been discharged 6.2 AE 8.2 days earlier. Of note, the most frequent initial antibiotic with anti-MRSA activity was vancomycin (50.2%), followed by linezolid (15.1%), clindamycin (10.8%) and teicoplanin (10.4%). Conversely, linezolid was the most frequently prescribed antibiotic among patients discharged with ongoing MRSA-active therapy (42.1% of cases). Both treatment duration and LOS tended to be shorter for patients who underwent an early switch from intravenous to oral therapy, with potential savings of s 2000 per early discharge-eligible patient [14] .
Data suggesting that oral shift from intravenous vancomycin to linezolid is associated with significant cost savings, mainly because of early discharge with a reduction of LOS, have been previously reported [17] [18] [19] [20] .
Linezolid currently represents the most common strategy for oral de-escalation in MRSA cSSTIs, because of the availability of an oral formulation that is as effective as the intravenous one [21] . Despite linezolid bacteriostiatic activity against a broad spectrum of Gram-positive pathogens, this molecule showed low resistance rates and high volume of distribution and excellent tissue penetration [22, 23] . Linezolid usually displays a favorable toxicity profile. Its use, however, presents some limitations in clinical practice, including: the risk of hematological side effects (mainly thrombocytopenia), in particular whenever treatment duration exceeds 2 weeks; the need for therapeutic drug monitoring (TDM) monitoring in order to avoid the risk of under-exposure and over-exposure (an increase in side adverse events has been documented for plasmatic levels above 8 mg/l); a high risk of drug interactions with selective serotonin reuptake inhibitors and other compounds with serotonergic activity, because of the inhibition of monoamine oxidase pathway [24] .
Tedizolid, a new generation oxazolidinone, has been recently approved by FDA and European Medicines Agency (EMA) for the treatment of cSSTIs based on the ESTABLISH-1 and ESTABLISH-2 studies, demonstrating that a 6-day course of once daily 200 mg tedizolid was statistically noninferior to a 10-day course of twice daily 600 mg linezolid for the treatment of cSSTIs [25, 26] . Compared with linezolid, tedizolid exerts a four-fold to eight-fold greater activity against a broad spectrum of Grampositive pathogens, including linezolid-resistant strains [27] . The major advantages of tedizolid include lower risk of myelotoxicity [28, 29] and fewer drug-drug interactions with compounds with serotoninergic activity and adrenergic agents compared with linezolid, because of a weak and reversible in-vitro inhibition of the monoamine oxidase pathway [30] . Moreover, tedizolid has once-daily administration because of the two-fold greater half-life compared with linezolid [31] . For all these reasons, tedizolid represents a promising option for early switch/early discharge strategies in patients with cSSTIs, particularly for those with underlying haematological alterations and/or potential drugdrug interactions.
Daptomycin is a cyclic lipopeptide and represents another suitable option OPAT and early discharge in cSSTIs because of MRSA, as suggested by recent data by Cervera et al. [32] . The currently Oral treatment switch and early hospital discharge Bassetti et al.
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www.co-infectiousdiseases.com approved daptomycin dose (4 mg/kg/day) has been associated with reduced clinical efficacy and increased risk of resistance selection [33, 34] . Thus, a daily dose of at least 6 mg/kg is currently recommended for the treatment of cSSTIs, with higher doses (up to 10 mg/kg/day) strongly suggested in bacteraemia and/or endocarditis and whenever daptomycin MICs are more than 0.25 mg/l [35] . Multiple-dose bolus injections over 10 s have been reported to be well tolerated and to have similar C max values as intravenous infusion over 30 min, thus, offering potential advantages, particularly in the setting of OPAT [36 & ]. Another attractive option for early discharge implementation is represented by the new lipoglycopeptides (dalbavancin and oritavancin), which are characterized by a prolonged half-life, allowing a single-dose intravenous treatment in patients with cSSTIs because of MRSA.
Both oritavancin and dalbavancin have been proved noninferior compared with vancomycin in phase-III, double-blinded, controlled trials [37, 38] . Oritavancin has been approved in Europe for the treatment of cSSTIs in January 2015. The recommended dose is a single, intravenous dose of 1200 mg administered as a 3-h infusion. Dalbavancin has been approved in the United States and Europe with a two-dose regimen of 1000 mg, followed 1 week by 500 mg on day 8. However, a recently published randomized controlled trial by Dunne et al. [39] demonstrated that a single 1500 mg infusion of dalbavancin is not inferior to the twodose regimen and shows similar safety profiles. These compounds exert a rapid, concentrationdependent bactericidal activity against a broad-spectrum of Gram-positive pathogens, including MRSA, through the inhibition of bacterial wall synthesis (transglycosylation and transpeptidation) and disruption of bacterial membrane function [40, 41] . Few side effects, mostly represented by nausea, vomiting, diarrhea, and headache, have been reported [37, 38] . Delafloxacin and omadacycline are new antibiotics currently under evaluation for the treatment of cSSTIs. Both compounds are characterized by the availability of an oral formulation and a broad-spectrum activity including MRSA, thus, representing attractive options for early switch/early discharge strategies.
Delafloxacin is a novel fluoroquinolone antibiotic characterized by a broad spectrum of Gram-positive pathogens (including MRSA and Enterococci) and Gram-negative pathogens [42] . Of note, because of a dual mechanism of DNA target inhibition (DNA gyrase and topoisomerase IV), delafloxacin remains highly effective also against levofloxacin-resistant S. aureus strains and has been associated with a reduced probability for selection of resistant in-vitro mutants [43] .
Delafloxacin has been recently approved by FDA for the treatment of cSSTIs based on a phase 3, randomized controlled trial showing noninferiority compared with vancomycin with aztreonam [44 && ]. Omoadacycline is a first-in-class aminomethylcycline antibiotic with microbiological activity against Gram-positive and Gram-negative aerobes and anaerobes [45] . Omoadacycline can be used in both intravenous and oral formulations and is currently under evaluation in phase 3, randomized, double-blind trials for the treatment of SSTIs versus linezolid [46, 47] . Table 2 summarizes new antimicrobial options for the management of SSTIs that offer potential early switch and/or early discharge.
Potential clinical scenarios for sequential therapy in SSTI allowing outpatient or oral administration are reported in Table 3 .
CONCLUSION
Optimization of management of SSTIs should include a combined knowledge of the pharmacokinetic and pharmacodynamic characteristics of relevant antimicrobials and a careful follow-up of patients treated for SSTIs to assess potential toxicity issues, including monitoring of drug concentrations, whenever applicable [48] .
New antibiotic options that have been approved for SSTIs offer promising characteristics to encourage early switch and early discharge, as well as to target drug-resistant Gram-positive bacteria such as MRSA. The new oxazolidinone tedizolid offers the option for intravenous to oral switch, once daily administration, and fewer side effects compared with linezolid in clinical trials. Dalbavancin and oritavancin belong to the class of lipoglycopeptides and present the opportunity of single administration and outpatient treatment, potentially avoiding hospitalization.
In conclusion, early switch and early discharge options are generally preferred by patients, have lower healthcare costs, reduce the risk of healthcare-associated complications and infections and are in line with antimicrobial stewardship programs [16] . In clinical practice, physicians should consider early clinical assessment of SSTI as part of a decisionmaking process, evaluating the likelihood of persistent clinical response, with the aim to determine the most effective approach for early hospital discharge, therefore, minimizing hospital-related costs and risks.
